Skip to main content
. 2024 Feb 16;11:1283389. doi: 10.3389/fped.2023.1283389

Table 1.

Evidence-based probiotic recommendations for children with DGBI: leading guidelines (ESPGHAN & WGO).

ESPGHAN 2023 (18) WGO 2023 (19)
Infant Colic management L. reuteri DSM 17938 (108 CFU/day for at least 21 days) for the management of infant colic in breastfed infants (certainty of evidence: moderate; grade of recommendation: weak).
B. lactis BB-12 (108 CFU/day, for 21–28 days) for the management of infant colic in breastfed infants (certainty of evidence: moderate; grade of recommendation: weak).
No recommendation can be made for or against the use of L. reuteri DSM 17938 in formula-fed infants due to insufficient evidence.		 L. reuteri DSM 17938 (108 CFU/day for at least 21 days). Oxford evidence level 1.
B. lactis BB-12 (108 CFU/day, for 21–28 days). Oxford evidence level 2.
L. rhamnosus 19070-2 and L. reuteri 12246 in a daily dose of 250 × 106 CFU 3.33 mg of fructooligosaccharide 250 × 10⁶ CFU respectively, plus 3.33 mg of fructooligosaccharide, for 28 days. Oxford evidence level 3.
L. paracasei DSM 24733, L. plantarum DSM 24730, L. acidophilus DSM 24735, L. delbrueckii subsp. bulgaricus DSM 24734), B. longum DSM 24736, B. breve DSM 24732, and B. infantis DSM 24737, and S. thermophilus DSM 24731. Oxford evidence level 3.
Infant Colic prevention No recommendation can be made for or against the use of any of the probiotics studied so far for preventing infant colic due to insufficient evidence. L. reuteri DSM 17938 108/day, to newborns each day for 90 days. Oxford evidence level 1.
Functional Abdominal Pain Disorders L. reuteri DSM 17938 (at a dose of 108CFU to 2 × 108 CFU/day) for pain intensity reduction in children with functional abdominal pain disorders (certainty of evidence: moderate; grade of recommendation: weak). Functional abdominal pain/IBS:
L. reuteri DSM 17938 108/day. Oxford evidence level 1. Oxford evidence level 1.
L. rhamnosus GG 109 UFC to 3 × 109 CFU twice daily. Oxford evidence level 1.
Functional Constipation Not recommendation can be made for the use of probiotics as a single or adjuvant therapy for treatment of functional constipation in children due to the lack of efficacy (certainty of evidence: moderate; grade of recommendation: weak). Not recommendation can be made for the use of probiotics in constipation in children.